Chapter 11. Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates

  1. Carlos Agustí2,3 and
  2. Antoni Torres2,3
  1. Gilles Hilbert,
  2. Didier Gruson and
  3. Frederic Vargas

Published Online: 7 JUL 2009

DOI: 10.1002/9780470714171.ch11

Pulmonary Infection in the Immunocompromised Patient: Strategies for Management

Pulmonary Infection in the Immunocompromised Patient: Strategies for Management

How to Cite

Hilbert, G., Gruson, D. and Vargas, F. (2009) Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates, in Pulmonary Infection in the Immunocompromised Patient: Strategies for Management (eds C. Agustí and A. Torres), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470714171.ch11

Editor Information

  1. 2

    Cap de Servei de Pneumologia i Allèrgia Respiratòria Hospital Clínic de Barcelona, Barcelona, Spain

  2. 3

    Institut Clinic de Pneumologia ICPCT, Hospital Clinic, C/Villarroel, 170, 08036 Barcelona, Spain

Author Information

  1. Division of Medical Intensive Care, University Hospital Bordeaux, Hôpital Pellegrin, Place Amelie Raba-Léon, F 33076 Bordeaux Cedex, France

Publication History

  1. Published Online: 7 JUL 2009
  2. Published Print: 27 JAN 2009

ISBN Information

Print ISBN: 9780470319574

Online ISBN: 9780470714171

SEARCH

Keywords:

  • intensive care management in immunocompromised patient;
  • invasive ventilation;
  • chronic obstructive pulmonary disease (COPD);
  • continuous positive airway pressure (CPAP);
  • NIV in immunocompromised patients with hypoxemic ARF;
  • NIV efficacy in immunocompromised patients with hypoxemic acute respiratory failure;
  • NIV as means of assisting ventilation in fibreoptic bronchoscopy

Summary

This chapter contains sections titled:

  • Introduction

  • Invasive ventilation

  • Rationale for NIV

  • Mechanisms of improvement with NIV in immunocompromised patients with acute respiratory failure

  • Clinical studies

  • Equipment and techniques: particularities in immunocompromised patients

  • Predictive factors of NIV outcome

  • Conclusions

  • References